| 翻訳と辞書 |
| DBV Technologies ： ウィキペディア英語版 |
DBV Technologies
DBV Technologies SA is a publicly owned, French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.〔(【引用サイトリンク】 title=DBV Technologies SA )〕〔(【引用サイトリンク】 title=DBV Technologies )〕〔(【引用サイトリンク】 title=Presentation )〕〔(【引用サイトリンク】 title=DBV Technologies and Centre d'Immunologie de Marseille-Luminy (CIML) enter in a Collaboration Agreement )〕〔(【引用サイトリンク】 title=Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy (VIPES) )〕
==History==
DBV Technologies was founded in 2002 by Doctor Pierre-Henri Benhamou (specializing in Pediatric Gastroenterology), the engineer Bertrand Dupont (from the Arts et Métiers ParisTech in Paris) and Professor Christophe Dupont (head of the Neonatology Department Saint Vincent Hospital, Paris).〔〔〔(【引用サイトリンク】 title=Pierre-Henri Benhamou, DBV Technologies )〕〔(【引用サイトリンク】 title=Management )〕
The founders provided initial startup capital.〔 Approximately €40M in venture funding was acquired between December, 2003 and January, 2011.〔In March 2012, an initial public offering on the NYSE Euronext exchange yielded €40.5M (Euros).〔
Dr. Benhamou presently serves as CEO and Mr. Dupont as CTO.〔〔
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「DBV Technologies」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|